Oncotarget

Research Papers:

CDC5L drives FAH expression to promote metabolic reprogramming in melanoma

PDF |  HTML  |  Supplementary Files  |  Order a Reprint

Oncotarget. 2017; 8:114328-114343. https://doi.org/10.18632/oncotarget.23107

Metrics: PDF 144 views  |   HTML 301 views  |   ?  

Zhichao Gu, Huafeng Zhang, Yong Li, Susu Shen, Xiaonan Yin, Wei Zhang, Ruimin Cheng, Yong Zhang, Xiaoyan Zhang, Hui Chen, Bo Huang, Yuchun Cao _

Abstract

Zhichao Gu1, Huafeng Zhang2, Yong Li3, Susu Shen1, Xiaonan Yin4, Wei Zhang1, Ruimin Cheng1, Yong Zhang1, Xiaoyan Zhang1, Hui Chen1, Bo Huang4 and Yuchun Cao1

1Department of Dermatology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China

2Department of Biochemistry and Molecular Biology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China

3Department of Oncology, Renmin Hospital, Hubei University of Medicine, Shiyan, Hubei 442000, China

4National Key Laboratory of Medical Molecular Biology and Department of Immunology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, Beijing 100005, China

Correspondence to:

Yuchun Cao, email: 963808187@qq.com

Keywords: fumarylacetoacetate hydrolase (FAH); anaplerotic reactions; cell division cycle 5-like protein (CDC5L); tumor metabolic reprogramming; melanoma

Received: August 09, 2017     Accepted: November 15, 2017     Published: December 07, 2017

ABSTRACT

Metabolic reprogramming allows tumor cells to thrive in the typically hypoxic tumor microenvironment. Using immunodetection and clinical data analyses, we demonstrate here that fumarylacetoacetate hydrolase (FAH) is highly expressed in melanoma and correlates with poor survival. FAH knockdown inhibits proliferation and migration, while promoting apoptosis in melanoma cells, result in prolonged survival in tumor-bearing mice. Molecular analyses using real time RT-PCR, western blot, and 13C tracing showed that these changes are driven by strong stimulation of anaplerotic reactions through the TCA cycle and the pentose-phosphate pathway, resulting in increased fatty acid and nucleotide synthesis. Using bioinformatic, ChIP-PCR, and gene silencing analyses, we determined that cell division cycle 5-like protein (CDC5L) is an important transcription factor regulating FAH expression in melanoma cells. These findings reveal that FAH induces metabolic reprogramming in melanoma and so emerges as both a potentially useful independent prognostic indicator and an attractive therapeutic target.


CDC5L drives FAH expression to promote metabolic reprogramming in melanoma | Gu | Oncotarget

INTRODUCTION

Melanoma, a malignant tumor that arises from melanocytes, is the most dangerous skin tumor, displaying high recurrence and a low survival rate that contribute to more than 50,000 deaths per year worldwide. Most researchers pinpoint excessive ultraviolet light exposure as the primary cause of melanoma, especially in people with low skin pigmentation. Current treatments include surgical removal, chemotherapy, radiotherapy, and immunotherapy, which are, especially at advanced tumor stages, characterized by poor efficacy. Therefore, there is an urgent need to define new therapeutic targets and prognostic indicators for this disease.

Increasing evidence suggests that metabolic reprogramming is a critical hallmark of tumor cells [13]. This phenomenon is considered to be largely regulated by oncogenic activation, which might be linked to specific transcription factor activity, signal transduction pathways, and/or epigenetic mechanisms [4]. Unlike normal cells, which have a comparatively low rate of glycolysis and derive their energy mainly from oxidation of pyruvate in the mitochondria, most cancer cells produce energy predominantly by enhanced glycolysis in the cytoplasm, even if oxygen is plentiful (i.e., the Warburg effect) [58]. Initially, the Warburg effect was thought to be the result of mitochondrial damage or shut-down mediated by cancer genes or other mechanisms [9]. However, mounting evidence demonstrated that mitochondrial functions, albeit frequently dysregulated in cancer cells, play essential biosynthetic roles in various tumors, especially in melanoma, and contribute to metabolic reprogramming by enhancing anaplerotic reactions [1013]. Anaplerotic reactions are chemical reactions that form biosynthetic intermediates within metabolic pathways such as the tricarboxylic acid (TCA) cycle. In the TCA cycle, concentrations of intermediates typically remain constant despite multiple biosynthetic reactions that utilize these molecules as substrates. Anaplerosis refers to the process of replenishing TCA cycle intermediates that have been extracted for biosynthesis through cataplerotic reactions [1, 13]. Four main reactions, catalyzed by pyruvate carboxylase (PC), aspartate transaminase, glutamate-dehydrogenase, methylmalonyl-CoA mutase, and adenylosuccinate lyase, have been described during anaplerosis [1]. The most important one among these is considered to be the irreversible carboxylation of pyruvate into oxaloacetate by PC [1416]. Anaplerotic flux must balance cataplerotic flux to maintain the homeostasis of multiple metabolic pathways, such as the TCA cycle, in normal tissues and in tumors such as melanoma [13, 17].

Fumarylacetoacetate hydrolase (fumarylacetoacetase; FAH) is an enzyme encoded by the FAH gene, which is located on chromosome 15q25.1 and contains 14 exons. FAH is the last enzyme in the sub-pathway of L-phenylalanine and tyrosine degradation, catalyzing the hydrolysis of 4-fumarylacetoacetate into fumarate and acetoacetate [18, 19]. Mutations in the FAH gene cause type I tyrosinemia [20], a hereditary metabolic condition characterized by increased tyrosine levels in the blood and urine of patients [21]. Once produced, fumarate can be converted to malate by fumarase (fumarate hydratase; FH) in the cytoplasm. Then, through transporters such as SLC25A1, SLC25A10, and SLC25A11 [22], or via citrate-malate antiport, malate may be directly transported into the mitochondria to participate in the TCA cycle. Alternatively, malate may be converted to pyruvate by malic enzyme (ME). Pyruvate then enters the mitochondria and is converted to oxaloacetate (OAA) via PC or to acetyl-CoA by the pyruvate dehydrogenase complex (PDC), to fuel the TCA cycle.

Whether FAH participates in anaplerotic reactions in melanoma cells remains unclear. In the present study, we evaluated FAH expression in clinical samples, conducted survival analyses in both patients’ data and a mouse melanoma model, and performed bioinformatics, real time RT-PCR, western blot and 13C tracing analyses to assess the role of FAH in human melanoma cells. Our results indicate that FAH transcription, driven by cell division cycle 5-like protein (CDC5L), is essential in the metabolic reprogramming of melanoma by promoting important anaplerotic reactions that sustain tumor growth and potentiate the disease’s severity.

RESULTS

FAH is highly expressed in melanoma and correlates with poor clinical outcomes

Analysis of a human melanoma tissue microarray by immunohistochemistry (IHC) with a FAH antibody revealed significantly higher, mainly cytosolic, FAH expression in melanoma than in benign nevus and normal skin (Figure 1A, Supplementary Figure 1, and Supplementary Table 1). Consistently, the same results were found in two different melanoma registries (Haqq and Talantov) listed in the Oncomine database (Figure 1B). To assess whether FAH levels correlate with clinical outcomes in melanoma patients, we obtained detailed FAH mRNA levels and survival information from 278 melanoma patients from TCGA Research Network (http://cancergenome.nih.gov/). The association between FAH levels and overall survival (OS) and disease-free survival (DFS) was estimated by Kaplan-Meier survival analysis. Data showed that patients with high FAH levels exhibited significantly shortened OS and DFS than those in which FAH expression was low (Figure 1C), suggesting the potential of FAH as an independent prognostic indicator for melanoma.

FAH expression is inversely associated with survival in both melanoma patients and melanoma-bearing mice.

Figure 1: FAH expression is inversely associated with survival in both melanoma patients and melanoma-bearing mice. (A) FAH expression by IHC in representative samples of a human melanoma tissue microarray. Data are expressed as mean IOD values; error bars represent SEM; ***p < 0.001 (Student’s t-test). (B) FAH mRNA expression in melanoma, nevus, and skin tissues from two different datasets (Haqq and Talantov) analyzed using the Oncomine database. Error bars indicate SEM; *p < 0.05; ***p < 0.001 (Student’s t-test). (C) FAH mRNA and survival information from 278 skin melanoma patients (TCGA database). D. Survival analysis of BALB/c-nude mice inoculated with melanoma cells stably expressing shRNA directed against FAH. Data are mean ± SEM; n = 8; *p < 0.05; ***p < 0.001 (Student’s t-test).

To model and test this association, we transduced human A375 and A875 melanoma cells with lentivirus expressing shRNA against FAH (shFAH) or scrambled (control) shRNA and then performed puromycin selection to establish stable clones. Successful construction of the lentiviral vectors was confirmed by direct nucleic acid sequencing (data not shown). FAH expression was confirmed by GFP detection using fluorescence microscopy, real-time RT-PCR, and western blot (Supplementary Figure 2A–2C). A tumor-bearing mouse model was then established by injecting shFAH-A375 or shFAH-A875 cells into the flanks of nude mice, and survival times were recorded. Consistent with the observations in patients, the survival time of FAH-silenced animals was longer than that of the control groups (Figure 1D). These results showed that high FAH expression is common in melanoma and is associated with shortened survival times in both patients and tumor-bearing mice.

FAH knockdown arrests cell cycle, reduces proliferation and migration, and increases apoptosis in melanoma cells.

Figure 2: FAH knockdown arrests cell cycle, reduces proliferation and migration, and increases apoptosis in melanoma cells. (A) Proliferation assay in melanoma cells transfected with FAH siRNA or scrambled siRNA and cultured in complete medium. Cell counts were obtained at different time points. (B) Transwell migration assay in melanoma cells transfected with FAH siRNA or scrambled siRNA. (C–D) Flow cytometric evaluation of cell cycle staging and apoptosis in melanoma cells transfected with FAH siRNA or scrambled siRNA. Data from 3 independent experiments are expressed as mean ± SEM; *p < 0.05; **p < 0.01; ***p < 0.001 (Student’s t-test).

FAH expression promotes proliferation, migration, and survival in melanoma cells

To investigate the impact of FAH fluctuations on melanoma cell growth and survival, we first knocked down FAH expression using two different siRNAs and analyzed proliferation, migration, apoptosis, and cell cycle staging. The silencing efficiency of both siRNAs was verified using real-time RT-PCR and western blot (Supplementary Figure 2D). Compared with the respective control groups, both proliferation and migration were significantly decreased in FAH-silenced A375, A875, and SK-MEL-1 cells, and these effects correlated with FAH silencing efficiency (Figure 2A2B). Interestingly, FAH knockdown or overexpression did not influence A375 cell proliferation in serum-free medium, suggesting that impaired migration does not result from decreased proliferation (Supplementary Figure 2E). We also detected the expression of several important proteins involved in epithelial-mesenchymal transition (EMT) in melanoma cells. For these, no noticeable expression changes were seen after FAH knockdown (Supplementary Figure 2F). We next evaluated the consequences of FAH silencing on cell cycle staging and apoptosis using flow cytometry. Results showed that in the melanoma cells the two siFAHs tested effectively reduced the number of cells in G2+S, while increasing the number of cells in G1 (Figure 2C). Meanwhile, Annexin V-FITC staining experiments showed that FAH knockdown was associated with increased apoptosis in the melanoma cell lines (Figure 2D).

Next, we increased the expression of FAH in melanoma cells using a plasmid vector (FAH-pcDNA3.1). Direct DNA sequencing (data not shown) and agarose gel electrophoresis (Supplementary Figure 2G) were used to validate the construct. Transfection efficiency was verified by real-time RT-PCR and western blot (Supplementary Figure 2G). FAH-pcDNA3.1 transfection did not affect proliferation in melanoma cells (Supplementary Figure 3A) but increased, as expected, their rate of migration compared with control cells (Supplementary Figure 3B). Cell cycle analysis showed a decreased G1 population, and an increase in the number of cells in G2+S phase (Supplementary Figure 3C), while no noticeable differences in the rate of apoptosis were observed between the FAH-overexpressing and control cells (Supplementary Figure 3D). We speculated that this phenomenon might be associated with sufficient endogenous FAH expression and limited substrates in melanoma cells. Thus, combined results from FAH silencing and overexpression experiments suggest that FAH promotes proliferation and migration, while inhibiting apoptosis in melanoma cells.

Analysis of FAH-regulated gene expression in melanoma cells

To shed light on the biological processes regulated by FAH, we performed mRNA expression profiling in control and FAH-knockdown melanoma cells. A375 cells were transfected in triplicate with siFAH or a scrambled siRNA for 72 h. Microarray analysis using Affymetrix GeneChip Human Gene 1.0 ST arrays identified 2535 DEGs after FAH silencing (Supplementary Table 2). Gene Ontology (GO) analysis was next employed to interrogate the biological functions of these DEGs. Significantly enriched GO terms were clustered based on their functional annotations. The data showed that for these 2535 DEGs, there were 512 functionally annotated clusters that were significantly enriched. The main clusters were involved in small molecule metabolic process, G1/S transition of cell cycle, cell proliferation, cellular response to hypoxia, cell migration, biosynthetic process, TCA cycle, and cell death (Figure 3A). Based on the Kyoto Encyclopedia of Genes and Genomes (KEGG) database, we further analyzed the pathways in which the DEGs were significantly enriched by applying the PathNet algorithm [23] (Figure 3B3C). In line with GO analysis results, DEG involvement was detected in 164 pathways, affecting cell cycle, apoptosis, the TCA cycle, tyrosine metabolism, and HIF-1 signaling, among others. Overall, these results suggest that FAH may affect multiple important biological functions and metabolic processes, including the TCA cycle, in melanoma cells.

GO and pathway interaction analyses.

Figure 3: GO and pathway interaction analyses. (A–B) GO and pathway analyses of differentially expressed genes (DEGs) in A375 cells after siRNA-mediated FAH silencing. GO analysis was applied to analyze the DEGs’ main functions. Pathway analysis was predominantly based on the KEGG database. The vertical axis represents categories and the horizontal axis represents -log 10 p values of significant GO terms or pathways. (C) Pathway network (PathNet) was constructed by connecting significant pathways including DEGs identified upon FAH knockdown. Circles represent pathways and lines indicate pathway interactions.

FAH promotes anaplerotic reactions and fatty acids synthesis in melanoma cells

FAH synthesizes fumarate and acetoacetate from L-phenylalanine and tyrosine. In the melanoma cells studied here, both immunostaining and western blot showed that FAH localized mainly in the cytosol, rather than the mitochondria (Figure 4A4B). We speculated that fumarate formed by FAH activity is converted to malate by fumarase (FH), which is then transported into the mitochondria, where it fuels anaplerotic reactions via the TCA cycle. To assess this hypothesis, we first analyzed the expression of fumarase in melanoma cells. Consistent with previous reports [24], western blots showed both cytosolic and mitochondrial fumarase expression (Figure 4C). On the other hand, and as expected, fumarate levels decreased after FAH knockdown (Figure 4D) and increased after ectopic FAH expression (Supplementary Figure 4A). Then, we accessed the cBioPortal for Cancer Genomics [25, 26] to evaluate and correlate mRNA levels of FAH and the oxoglutarate/malate carrier SLC25A11 in cutaneous melanoma data from TCGA. Results showed that indeed, the mRNA levels of FAH were positively correlated with those of SLC25A11 (Figure 4E).

FAH expression modulates TCA cycle enzyme and transport activity.

Figure 4: FAH expression modulates TCA cycle enzyme and transport activity. (A) A375 cells were stained with FAH or COX-IV antibodies and photographed under a two-photon confocal microscope. Scale bars, 5 μm. (B) Western blot analysis of FAH expression in cytosolic and mitochondrial fractions isolated from A375, A875, and SK-MEL-1 melanoma cells. β-actin and COX-IV served as cytosolic and mitochondrial markers, respectively. (C) Western blot analysis of β-actin, COX-IV, and fumarase in cytosolic and mitochondrial fractions of A375, A875, and SK-MEL-1 melanoma cells. (D) Total cellular fumarate levels in siFAH-transfected melanoma cells. (E) FAH and SLC25A11 mRNA data from clinical samples of melanoma (TCGA database). (F) Expression profiling of FAH, FH, SLC25A1, SLC25A10, SLC25A11, ME1, ME2, PC, PDHX, PDPR, PDHB, and PDHA1 mRNAs in FAH-silenced A375 cells. (G) Western blot analysis of FAH, FH, ME1, PC, and PDHB in siFAH-transfected A375 cells. (H) Real-time RT-PCR analysis of FAH, FH, ME1, PC, PDHB, SLC25A1, SLC25A10, and SLC25A11 mRNAs in siFAH-transfected A375 cells. Data are presented as mean ± SEM; n = 3. *p < 0.05; **p < 0.01; ***p < 0.001 (Student’s t-test).

Next, we performed mRNA expression profiling in FAH-silenced A375 cells, and found that the expression of multiple enzymes, including FH, malic enzyme (ME1 and ME2), pyruvate dehydrogenase complex (PDHB, PDHX, PDPR, and PDHA1), pyruvate carboxylase (PC), and the mitochondrial carrier proteins SLC25A1, SLC25A10, and SLC25A11, was downregulated after FAH knockdown (Figure 4F). To validate these findings, we performed real-time RT-PCR and western blot in FAH-silenced or FAH-overexpressing A375 cells. Consistently, results showed that the expression of FH, ME1, PC, PDHB, SLC25A1, SLC25A10, and SLC25A11 was largely decreased after FAH silencing (Figure 4G4H) and slightly increased after FAH overexpression (Supplementary Figure 4B–4C). These results suggested that FAH activity effectively provides intermediates for the TCA cycle.

We next accessed cutaneous melanoma data from TCGA and asked whether FAH can accelerate metabolic flux through the TCA cycle by analyzing, at the mRNA level, the correlation between FAH and the enzymes involved in the TCA cycle. Interestingly, rate-limiting enzymes of the TCA cycle, including citrate synthase (CS), isocitrate dehydrogenase (IDH3A, IDH3B, and IDH3G) and the a-ketoglutarate dehydrogenase complex (OGDH, DLST, and DLD), were all found to be positively associated with FAH (Figure 5A). Moreover, other TCA cycle enzymes, such as malate dehydrogenase (MDH), aconitase (ACO2), succinyl-CoA synthetase (SUCLG1 and SUCLG2), succinate dehydrogenase (SDHA, SDHB, SDHC, and SDHD) and FH, also displayed a positive correlation with FAH (Figure 5A and Supplementary Figure 5A). These results were followed by analyses of mRNA expression profiling in FAH-silenced A375 cells, which showed that the expression of the TCA cycle enzymes mentioned above was indeed downregulated after FAH knockdown (Figure 5B). We next performed real-time RT-PCR and western blot in FAH-silenced or overexpressing A375 cells. As expected, a clear decrease in the expression of rate-limiting enzymes of the TCA cycle was observed after FAH knockdown (Figure 5C5D) while a slight increase occurred instead in FAH-overexpressing cells (Supplementary Figure 5B-–5C).

FAH knockdown reduces flux through the TCA cycle and inhibits fatty acids synthesis.

Figure 5: FAH knockdown reduces flux through the TCA cycle and inhibits fatty acids synthesis. (A) FAH, CS, IDH3A, IDH3B, IDH3G, OGDH, DLST, DLD, and FH mRNA data from clinical samples of melanoma (TCGA database). (B) Expression profiling of ACLY, ACACA, ACACB and TCA cycle enzymes’ mRNAs in FAH-silenced A375 cells. (C) Quantification of CS, OGDH, DLST, and IDH3B mRNAs by real-time RT-PCR in siFAH-transfected A375 cells. (D) Western blot analyses of FAH, CS, OGDH, IDH3A, ACLY, and ACACA expression in siFAH-transfected A375 cells. (E) Analysis of the relative abundance of 13C-labeled citrate, malate, and fumarate in A375 cells transfected with siFAHs. Cells were cultured with 13C-D-glucose for 24 hours and analyzed by LC-MS. (F) Quantification of ACLY, ACACA and ACACB mRNAs by real-time RT-PCR in siFAH-transfected A375 cells. Results are expressed as mean ± SEM of samples assessed in triplicates. Representative data from three separate experiments are shown. *p < 0.05; **p < 0.01; ***p < 0.001 (Student’s t-test).

To further validate the contribution of FAH to metabolic flow through the TCA cycle, we performed 13C tracing by Liquid Chromatography Q-Exactive Mass Spectrometry (LC-QE-MS) in A375 cells using 13C-D-glucose. Through this approach, TCA cycle intermediates would obtain after each cycle two 13C atoms from acetyl coenzyme A (acetyl-CoA), derived from glycolysis of 13C-D-glucose. Hence the relative abundance of intermediates containing two (m+2), four (m+4), or six (m+6) 13C atoms represents the metabolic flow rate of the TCA cycle. Results showed that the relative abundance of citrate, malate, or fumarate containing two (m+2) or four (m+4) 13C atoms was decreased after FAH knockdown (Figure 5E) and slightly increased after FAH overexpression (Supplementary Figure 5D), indicating deceleration and acceleration, respectively, of the TCA cycle. This suggests that FAH effectively increases TCA cycle activity. Together, these results indicate that FAH stimulates energy metabolism and biosynthesis, affecting multiple biological behaviors in melanoma.

Citrate is an essential intermediate in the TCA cycle that is transported from the mitochondria to the cytoplasm by SLC25A1 [22] to be broken down into acetyl-CoA by the enzyme ATP-citrate lyase (ACLY). Acetyl-CoA, in turn, is converted into malonyl-CoA by acetyl-CoA carboxylases (ACACA and ACACB), which is the rate-limiting step in fatty acid biosynthesis. Since the above studies have demonstrated that FAH effectively promotes anaplerotic reactions, we speculated that FAH activity may also lead to increased citrate levels in mitochondria and subsequently influence fatty acids synthesis. This hypothesis was tested by analyzing mRNA expression profiling data in FAH-silenced A375 cells. Results showed that the expression of ACLY, ACACA, and ACACB were decreased after FAH knockdown (Figure 5B). These findings were corroborated by real-time RT-PCR and western blot, (Supplementary Figure 5D and 5F) which showed increased ACLY, ACACA, and ACACB levels after FAH overexpression (Supplementary Figure 5C and 5E). These data indicated that FAH promotes fatty acids synthesis from citrate in melanoma cells.

Enhanced FAH expression stimulates glycolysis, the pentose phosphate pathway, and nucleotide synthesis in melanoma cells

We next asked if in addition to the TCA cycle, FAH activity may affect other glucose-utilizing metabolic pathways, such as glycolysis and the pentose phosphate pathway (PPP), an important branch of glycolysis that provides the nucleotide precursor ribose 5-phosphate and is a major source of cytosolic NADPH. To address this question, we further analyzed mRNA expression profiling data in FAH-silenced A375 cells. Results showed that levels of the glucose transporters (SLC2A family) and related enzymes involved in glycolysis, the PPP pathway, and nucleotide synthesis, such as the rate-limiting enzymes hexokinase (HK), phosphofructokinase (PFKL, PFKM, and PFKP), pyruvate kinase (PKM), lactate dehydrogenase (LDH), glucose-6-phosphate dehydrogenase (G6PD) and phosphoribosyl pyrophosphate synthetase (PRPS1 and PRPS2), were mostly decreased after FAH knockdown (Figure 6A). In parallel, real-time RT-PCR and western blot analyses confirmed a decrease in the expression of SLC2A1 and the above mentioned enzymes after FAH knockdown (Figure 6B6C), whereas an increase, in contrast, was observed in A375 cells after FAH overexpression (Supplementary Figure 6A–6C).

FAH knockdown inhibits glycolysis, pentose phosphate pathway activity, and nucleotide synthesis in melanoma cells.

Figure 6: FAH knockdown inhibits glycolysis, pentose phosphate pathway activity, and nucleotide synthesis in melanoma cells. (A) Expression profiling of glycolytic, PPP, and nucleotide biosynthetic enzymes’ mRNAs in FAH-silenced A375 cells. (B) Quantification of SLC2A1, HK2, PFKP, PFKM, PKM, LDHA, G6PD, PGD, PRPS1, and PRPS2 mRNAs by real-time RT-PCR in siFAH-transfected A375 cells. (C) Western blot analysis of FAH, SLC2A1, HK2, PFKM, PKM, G6PD, and PRPS1 in siFAH-transfected A375 cells. (D) Analysis of the relative abundance of 13C-labeled lactate in siFAH-transfected A375 cells. Cells were cultured with 13C-D-glucose for 24 hours and analyzed by LC-MS. (E) Determination of glucose consumption rate in siFAH-transfected A375 cells. Data are expressed as mean ± SEM; n = 3 independent experiments. *p < 0.05; **p < 0.01; ***p < 0.001 (Student’s t-test).

Next, 13C tracing experiments were done in A375 cells to functionally validate these results. Here, glycolysis intermediates should incorporate three or six 13C atoms from 13C-D-glucose, hence the relative abundance of lactic acid containing three (m+3) 13C atoms represents glycolytic flow rate. In line with mRNA and protein expression results, 13C-labeled (m+3) lactate was decreased after FAH knockdown (Figure 6D) and slightly increased after FAH overexpression (Supplementary Figure 6D); these results indicated, respectively, reduced and increased glycolytic rates. In addition, we evaluated glucose consumption rate using enzymatic methods. Results showed that the glucose consumption rate of A375 cells was decreased after FAH knockdown (Figure 6E) and slightly increased after FAH overexpression (Supplementary Figure 6E).

These results demonstrated that FAH effectively stimulates glycolysis, the PPP pathway, and nucleotide synthesis, and increases glucose consumption in melanoma cells.

CDC5L drives FAH expression in melanoma

Mammalian cell division cycle 5-like protein (CDC5L), a functional homolog of the Schizosaccharomyces pombe cdc5 gene, has been shown to act as a positive regulator of G2/M progression and is a basic component of the non-snRNA spliceosome [27, 28]. In addition, CDC5L shares significant homology with the transcription factor c-Myb, indicating a potential role in regulating gene transcription [29, 30]. Upon searching the SABiosciences proprietary database (using the SABiosciences Text Mining Application and the UCSC Genome Browser) we found that CDC5L is one of the major predicted transcriptional factors for the FAH gene. The binding site of CDC5L on the FAH gene is located at chr15: 80430676-80430688 and the binding sequence is as follows: TTTATGTTTATTC (Figure 7A). To test the hypothesis that CDC5L is an important transcription factor for the FAH gene [31], chromatin immunoprecipitation (ChIP) and real-time PCR analysis were performed in melanoma cells. Because specific immunoprecipitation human CDC5L antibodies are not available, we constructed recombinant plasmids containing hemagglutinin- (HA) tagged CDC5L (pCMV-C-HA-CDC5L-CDS) and validated them by direct DNA sequencing (data not shown). Then we transfected this vector into A375 cells and conducted ChIP-qPCR using primers for the predicted binding sequence of the FAH gene (Supplementary Table 3). Clear amplification of a 120-bp DNA region including the predicted binding site was obtained from anti-HA precipitates, whereas anti-IgG antibody precipitates yielded negligible amplification of this DNA region (Figure 7B). These data indicated that CDC5L protein specifically binds to the FAH gene in vitro. To further confirm that CDC5L increases FAH expression, we knocked down the Cdc5l gene in melanoma cells using two siRNAs (Figure 7C and 7E), and analyzed FAH expression by real-time RT-PCR and western blot. Results showed that the expression of FAH was significantly decreased at both the mRNA (Figure 7D) and protein (Figure 7E) levels at different time points, suggesting that CDC5L effectively drives the expression of the FAH gene.

CDC5L drives FAH expression in melanoma cells.

Figure 7: CDC5L drives FAH expression in melanoma cells. (A) CDC5L binding sequence and location on the FAH gene, determined using the SABiosciences database. (B) ChIP-qPCR assay. DNA fragments interacting with CDC5L protein were pulled down by an anti-HA antibody and amplified by real-time PCR. Total chromatin was used as input. Normal human IgG served as negative control. (C–E) Silencing efficiency of two CDC5L siRNAs assessed by real-time RT-PCR (C) and western blot (E) at 48 and 72 h, respectively. These samples were then used to detect FAH expression using real-time RT-PCR (D) and western blot (E). Data are expressed as the mean ± SEM of three independent experiments. *p < 0.05; **p < 0.01; ***p < 0.001 (Student’s t-test).

DISCUSSION

Anaplerotic reactions are essential for replenishing TCA cycle intermediates; they maintain the homeostasis of multiple metabolic pathways and are crucial for the survival and proliferation of tumor cells. The production of oxaloacetate from pyruvate by PC is considered the most physiologically important event within these pathways. Although multiple anaplerotic reactions have been identified in tumor cells, many of the enzymes involved remain to be identified.

In this study, we found that FAH is highly expressed in clinical specimens of melanoma, where it correlates with shortened survival times and may thus serve as an independent prognostic biomarker. Subsequently, our in vitro studies using three human melanoma cell lines revealed that FAH regulates important biological processes such as proliferation, migration, and apoptosis. Furthermore, we show that disrupting FAH in melanoma cells effectively prolongs survival in tumor-bearing mice. We attribute the pro-tumoral actions of FAH to its ability to promote anaplerotic reactions that underlie metabolic reprogramming in melanoma cells.

Little is known about the global metabolic impact of FAH on tumor cells. FAH catalyzes the conversion of 4-fumarylacetoacetate to acetoacetate and fumarate from L-phenylalanine and tyrosine catabolism. Through FAH knockdown and overexpression experiments combined with real time RT-PCR, western blot, and 13C metabolic flux analyses, the present study reveals that a remarkable number of enzymes within the glycolytic, TCA cycle, PPP, and nucleotide biosynthetic pathways are affected by fluctuations in cellular FAH levels in melanoma cells.

Based on sequence interaction evidence from genome data analyses, our ChIP-qPCR analysis confirmed that CDC5L binds to the FAH gene and drives FAH expression in A375 cells. Accordingly, disrupting CDC5L using siRNA significantly downregulated FAH levels. A transcription factor function for CDC5L has been previously suggested, but not clearly proved, based on sequence homology with c-Myb [29, 30]. Interestingly, since the binding site of CDC5L on the FAH gene is at a relatively distant position upstream of the transcription initiation point, i.e. at an unusual region of the gene’s promoter, we speculate that CDC5L might not bind to FAH’s promoter, but to other cis-regulatory elements (CREs) such as enhancers or silencers [3234]. Thus, although the present data indicate that CDC5L is a putative transcription factor for FAH, detailed confirmatory experiments are warranted. Our next studies will also address the potential role of FAH in the regulation of hypoxia-inducible factor (HIF) target genes, as the elevated level of fumarate derived from increased FAH expression are likely to inhibit prolyl hydroxylase (PHD), preventing HIF degradation [3538]. Stabilized HIF-1α is translocated to the nucleus and activates transcription of target genes including genes of glycolysis, glucose uptake and other metabolic pathways [3941].

In summary, consistent with clinical evidence linking FAH overexpression with shortened melanoma patient survival, our study revealed that FAH plays a critical role in melanoma cell growth and survival by stimulating anaplerotic reactions that lead to increased energy metabolism and enhanced biosynthesis of fatty acids and nucleotides. The present study offers novel insights into melanoma’s metabolic reprogramming, and suggests that FAH is both a useful independent prognostic biomarker and a relevant target for melanoma therapy.

MATERIALS AND METHODS

Cell lines and animals

Human melanoma A375 cells were a kind gift of the Department of Oncology, Union Hospital (Wuhan, China). A875 and SK-MEL-1 cells were purchased from the Cell Resource Center, Institute of Basic Medical Sciences, CAMS/PUMC (Beijing, China). All cells were checked for mycoplasma and interspecies cross-contamination, and authenticated by short tandem repeat (STR) profiling and isoenzyme analyses at the Cell Resource Center and at the China Center for Type Culture Collection (Wuhan, China) before the study started, and occasionally during the course of this research. A375, A875, and SK-MEL-1 cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM, Gibco, Grand Island, NY) supplemented with 10% fetal bovine serum (Gibco). All cell lines were maintained in culture for a maximum of 20 passages (two months). Female BALB/c-nude mice (5 to 7 weeks old) were purchased from HFK Bioscience (Beijing, China). Animal studies were approved by the Animal Care and Use Committee of Tongji Medical College (Wuhan, China).

RNA interference

A375 and A875 cells stably expressing short hairpin RNAs (shRNAs) against FAH and GFP were generated through lentiviral infection and puromycin selection. The shRNA-expressing virus was constructed by GeneChem (Shanghai, China), and direct sequence analysis was used to verify the inserted sequences. Melanoma cells were stably transduced with viral supernatant (MOI = 10, diluted to 107 TU/ml with 10% FBS/DMEM; 8 μg/ml polybrene) and fresh 10% FBS/DMEM was added after 12 h. Thereafter, selection with 2 μg/ml of puromycin was initiated at 48 h and allowed to continue for 3 to 5 days. Stably transduced cells were maintained in 10% FBS/DMEM with 1 μg/ml puromycin. Silencing efficiency was verified by GFP detection, western blot, and real-time RT-PCR.

For FAH and CDC5L knockdown, siRNAs against these two genes and negative control siRNAs were purchased from RiboBio (Guangzhou, China). The corresponding sequences are shown in Supplementary Table 3. Cells were transfected with siRNAs using Lipofectamine 3000 (Invitrogen, Carlsbad, CA, USA) at a final concentration of 50 nmol/L. Silencing efficiency was verified by western blot and real-time RT-PCR.

Microarray assay

Total RNA from A375 cells transfected with FAH-targeted siRNA (siFAH) or negative control siRNA was extracted using the miRNeasy Mini Kit (Qiagen, Hilden, Germany) and further purified with an RNase-Free DNase Set. RNA quality was assessed by agarose gel electrophoresis. Subsequently, biotinylated cDNA was prepared according to the standard Affymetrix (Santa Clara, CA, USA) protocol from 250 ng of total RNA using a GeneChip® WT PLUS Reagent Kit. Following labeling, 5.5 μg of cDNA was hybridized for 16 h at 45°C on a GeneChip Human Gene 1.0 ST Array in a GeneChip® Hybridization Oven 645. GeneChips were washed and stained in an Affymetrix Fluidics Station 450. We assayed three biological replicates for each sample. All arrays were then scanned using a GeneChip® Scanner 3000 (Affymetrix). Data were analyzed with the Robust Multichip Analysis (RMA) algorithm using Affymetrix default analysis settings and global scaling as the normalization method.

Bioinformatic analysis

DEGs were identified based on SAM (Significance Analysis of Microarrays). Afterwards, we selected DEGs based on ≥ 1.2-fold-change in either direction, and DEGs for which p < 0.05 were considered downregulated or upregulated.

Gene Ontology (GO) analysis was applied for DEG functional analysis. Statistical significance (defined as p < 0.05) was assessed using Fisher’s exact test and multiple comparison tests, with a false discovery rate (FDR) < 0.05 as a cut-off. We calculated the enrichment (Re) score to determine the enrichment level per GO term using the following formula: Re = (nf/n)/(Nf/N), where nf is the number of target genes within a particular category, n is the total number of genes within the same category, Nf is the number of target genes in the entire microarray, and N is the total number of genes in the microarray. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis was used to identify significant pathways related to the DEGs. Again, we used Fisher’s exact test and multiple comparison test to select significant pathways with p < 0.05. Re was calculated using the equation above. GO and KEGG pathway analyses were conducted using the online analysis tool Gene Cloud of Biomedical information (GCBI; https://www.gcbi.com.cn). The microarray data presented in this study have been deposited in the NCBI Gene Expression Omnibus and are accessible through GEO Series accession number GSE86870 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE86870).

Human melanoma tissue samples’ mRNA values were obtained from the Oncomine database. Survival data and related gene expression values from melanoma patients were obtained from The Cancer Genome Atlas (TCGA) database. The binding position and sequence of CDC5L in the FAH gene were obtained from the SABiosciences proprietary database.

Plasmid constructs and transfection

FAH overexpression vectors were constructed by Goodbio Company (Wuhan, China) by inserting human FAH cDNA into pcDNA3.1 plasmids. The human CDC5L (NM_001253.3) CDS without the stop codon was amplified, double-digested with SmaI and XbaI, and then cloned into the pCMV-C-HA vector (Beyotime, Shanghai, China) to construct the pCMV-C-HA-CDC5L-CDS vector. Lipofectamine 3000 (Invitrogen) was used to transfect the plasmids into melanoma cells. All constructs were subjected to direct sequence analysis to verify the identities of the inserted sequences.

In vitro migration assay

Complete medium (DMEM containing 10% FBS; 600 μl) was added to the lower chamber of 24-well transwell plates (Corning, NY, USA). Then, 5 × 104 melanoma cells resuspended in 100 μl of serum-free DMEM were seeded into the upper chambers in triplicate and incubated at 37°C. A375 cells were incubated for 24 h, whereas A875 cells were incubated for 48 h because of their lower migration capacity. After being washed with phosphate-buffered saline (PBS), the cells were fixed using 4% neutral paraformaldehyde for 30 min and stained with 0.1% crystal violet for 20 min. Tumor cells migrating into the lower surface of the membranes were photographed at 100x magnification. Cells in ten random fields were counted to quantify migration.

Cell cycle analysis

Cells were alternatively transfected with two siFAH or FAH-overexpressing plasmids for 60 h, trypsinized, washed with PBS, and fixed with cold (–20°C) 70% ethanol. After 20 h, cells were labeled using a Cell Cycle Detection Kit (KeyGen Biotech, Nanjing, China) according to the manufacturer’s instructions. Cell DNA contents were measured on an Accuri C6 flow cytometer (BD Biosciences, Ann Arbor, MI, USA). The percentages of cells in G1, S, and G2 phases were determined using FlowJo 7.6 software.

Apoptosis analysis

Cells were alternatively transfected with two siFAH or FAH-overexpressing plasmids for 60 h and labeled using an Annexin V-FITC Apoptosis Detection Kit (KeyGen Biotech) according to the manufacturer’s protocol. Apoptosis levels were analyzed on an Accuri C6 flow cytometer.

Semi-quantitative PCR and real-time RT-PCR

Cells were lysed in TRIzol reagent (Invitrogen), and total RNA was extracted following the manufacturer’s instructions. Real-time PCR analyses were performed with SYBR Green PCR master mix (Toyobo, Osaka, Japan) using a Bio-Rad CFX ConnectTM Real-Time PCR Detection System (Bio-Rad, Mississauga, ON, Canada). Comparative quantitative mRNA levels were normalized to the housekeeping gene β-actin. Primer sequences are shown in Supplementary Table 3.

Cellular fumarate detection

Total cellular fumarate levels were determined using the Fumarate Detection Assay Kit (Sigma-Aldrich, St. Louis, MO, USA) following the manufacturer’s protocol. Briefly, cells were homogenized in Fumarate Assay Buffer and then centrifuged to remove insoluble material. Then we set up the Master Reaction Mix which including Fumarate Developer, Enzyme Mix, and Assay Buffer. The samples and the Master Reaction Mix were mixed, incubated at 37°C for 60 min, after which absorbance was measured at 450 nm.

Glucose consumption assay

Melanoma cells were alternatively transfected with two siFAH or FAH-overexpressing plasmids for 24 h. After complete medium exchange, a cell-free control group was set. Following a 24 h incubation, the supernatants were collected and glucose concentration was measured using a Glucose Assay Kit (Sigma) according to the manufacturer’s instructions. Cells were lysed for protein quantification using a BCA Protein Assay Kit (Thermo Scientific, Rockford, IL, USA). Glucose consumption rate was determined as the glucose concentration in the supernatants minus that of the cell-free control group, and normalized to total protein levels.

Tissue microarray and immunohistochemistry

A human melanoma tissue microarray was purchased from Alenabio Biotechnology Co. (Xi’an, China). Immunohistochemistry using an anti-human FAH antibody (Abcam, Cambridge, MA, USA) was conducted by Goodbio Co. (Wuhan, China). IOD values of microarray samples were determined with IPP 6.0 software. Detailed information on the patient samples included in the microarray and corresponding IOD values is provided in Supplementary Table 1.

Western blot analysis

Cytosolic and mitochondrial fractions were isolated from melanoma cells using the Cell Mitochondria Isolation Kit (Beyotime, Shanghai, China). Western blot was performed as described previously [42]. Proteins were extracted and analyzed using antibodies targeting the following human proteins: FAH (Abcam), COX-IV (Beyotime), FH, ME1, PC, PDHB, CS, OGDH, IDH3A, ACACA, ACLY, HK2, PFKM, PKM, SLC2A1, G6PD, PRPS1, CDC5L (Proteintech, Wuhan, China), N-Cadherin, E-Cadherin, TCF8/ZEB1 (Cell Signaling Technology, Beverly, MA, USA), and β-actin (Abcam) at the recommended dilutions.

Two-photon confocal microscopy

A375 cells were stained with anti-human FAH (Abcam) and anti-human COX-IV (Beyotime) antibodies according to the manufacturer’s instructions and visualized by two-photon confocal microscopy (Leica, Wetzlar, Germany).

13C tracing by Liquid Chromatography Q-Exactive Mass Spectrometry (LC-QE-MS)

For 13C tracing experiments, A375 cells were alternatively transfected with two siFAHs or FAH-overexpressing plasmids for 48 h. After washing, cells were cultured with D-glucose (U-13C6, 99%; Cambridge Isotope Laboratories, Inc., Andover, MA, USA) for 24 h. Cells were trypsinized, washed twice with PBS and lysed in extraction solvent (80% methanol/water) for 30 min at –80°C. After centrifugation at 13,000 g (10 min at 4°C), supernatant extracts were analyzed using LC-QE-MS. Briefly, liquid chromatography was performed using a HPLC system (Ultimate 3000 UHPLC) (Thermo Fisher Scientific, San Jose, CA, USA) equipped with an XBridge amide column (100 × 2.1 mm i.d., 3.5 μm; Waters). The column temperature was maintained at 10 °C. The mobile phase A was 20 mM ammonium acetate and 15 mM ammonium hydroxide in water with 3% acetonitrile, pH 9.0, and the mobile phase B was acetonitrile. The linear gradient was as follows: 0 min, 85% B, 1.5 min, 85% B, 5.5 min, 30% B, 8 min, 30% B, 10 min, 85% B, and 12 min, 85% B. The flow rate was 0.2 mL/min. Sample volumes of 5 μl were injected for LC-MS analysis on a Q-Exactive mass spectrometer (Thermo Fisher Scientific) equipped with a HESI probe; the relevant parameters were: heater temperature, 120 °C; sheath gas, 30; auxiliary gas, 10; sweep gas, 3; and spray voltage, 2.5 kV for the negative mode. A full scan ranging from 80 to 350 (m/z) was used. Resolution was set at 70,000. Data were quantified by integrating the area under the curve of each compound using Xcalibur Qual Browser (Thermo Fisher). Each metabolite’s accurate mass ion and subsequent isotopic ions were extracted (EIC) using a 10 ppm window.

Chromatin immunoprecipitation (ChIP) and qPCR analysis

As specific anti-human CDC5L antibodies for immunoprecipitation studies are not available, we constructed pCMV-C-HA-CDC5L-CDS plasmids and transfected them into A375 cells using Lipofectamine 3000. ChIP was performed using the EZ-ChIP Kit (Millipore, Billerica, MA, USA). The AVCX130 system (Sonics & Materials, Newtown, CT, USA) was used for cell sonication. Anti-HA (Abcam) and normal anti-human-IgG (Millipore) antibodies were used for immunoprecipitation reactions. The DNA fragments recovered from immunoprecipitated complexes were amplified via real-time PCR (qPCR). The primer sequences are listed in Supplementary Table 3.

Statistical analysis

Statistical analysis was performed using SPSS 17.0 or GraphPad Prism 6.0 statistical software. All data are presented as mean ± standard error of the mean (SEM). Differences in mRNA expression between groups were calculated using a two-tailed Student’s t-test. Survival curves were plotted using the Kaplan-Meier method and compared by the log-rank test. For all tests, statistical significance was set at p < 0.05.

Abbreviations

FAH: fumarylacetoacetate hydrolase; FH: fumarase; acetyl-CoA: acetyl coenzyme A; SLC25A1: solute carrier family 25 (mitochondrial carrier; citrate transporter), member 1; SLC25A10: solute carrier family 25 (mitochondrial carrier; dicarboxylate transporter), member 10; SLC25A11: solute carrier family 25 (mitochondrial carrier; oxoglutarate carrier), member 11; ME: malic enzyme; PC: pyruvate carboxylase; PDHX: pyruvate dehydrogenase complex, component X; PDPR: pyruvate dehydrogenase phosphatase regulatory subunit; PDHB: pyruvate dehydrogenase beta; PDHA1: pyruvate dehydrogenase alpha 1; CS: citrate synthase; ACO2: aconitase 2; IDH: isocitrate dehydrogenase; OGDH: oxoglutarate dehydrogenase; DLST: dihydrolipoamide S-succinyltransferase; DLD: dihydrolipoamide dehydrogenase; SUCL: succinate-CoA ligase; SDH: succinate dehydrogenase complex; MDH: malate dehydrogenase; ACLY: ATP citrate lyase; ACACA: acetyl-CoA carboxylase alpha; ACACB: acetyl-CoA carboxylase beta; SLC2A1: solute carrier family 2 (facilitated glucose transporter), member 1; HK: hexokinase; GPI: glucose-6-phosphate isomerase; PFK: phosphofructokinase; ALDO: aldolase; TPI: triosephosphate isomerase; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; PGK: phosphoglycerate kinase; PGAM: phosphoglycerate mutase; ENO: enolase; PKM: pyruvate kinase; LDH: lactate dehydrogenase; G6PD: glucose-6-phosphate dehydrogenase; PGLS: 6-phosphogluconolactonase; PGD: phosphogluconate dehydrogenase; TKT: transketolase; PRPS: phosphoribosyl pyrophosphate synthetase; PPAT: phosphoribosyl pyrophosphate amidotransferase; GART: phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase; PFAS: phosphoribosylformylglycinamidine synthase; PAICS: phosphoribosylaminoimidazole succinocarboxamide synthetase; ADSL: adenylosuccinate lyase; ATIC: 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase; DEGs: differentially expressed genes; TCGA: The Cancer Genome Atlas; OS: overall survival; DFS: disease-free survival; GFP: green fluorescent protein; siRNA: small interfering RNA; shRNA: short hairpin RNA; TCA cycle: tricarboxylic acid cycle; real-time RT-PCR: quantitative reverse transcription-PCR; PPP: pentose phosphate pathway; CDC5L: Cell division cycle 5-like protein; CDS: coding DNA sequence; HA: hemagglutinin; CREs: cis-regulatory elements; HIF: hypoxia-inducible factor; PHD: prolyl hydroxylase; STR: short tandem repeat; GO: Gene Ontology; KEGG: Kyoto Encyclopedia of Genes and Genomes; cDNA: complementary DNA; IOD: integrated optical density;

Author contributions

Conception and design: Yuchun Cao, Zhichao Gu, Bo Huang, Yong Li

Development of methodology: Yuchun Cao, Zhichao Gu, Huafeng Zhang

Acquisition of data (provided animals, recruited and managed patients, provided facilities, etc.): Zhichao Gu, Susu Shen, Wei Zhang, Xiaonan Yin, Ruimin Cheng, Yong Zhang, Xiaoyan Zhang, Hui Chen, Yuchun Cao, Bo Huang

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analyses): Zhichao Gu, Huafeng Zhang, Yong Li, Yuchun Cao

Writing, review, and/or revision of the manuscript: Zhichao Gu, Yong Li, Huafeng Zhang, Yuchun Cao

Administrative, technical, or material support: Bo Huang, Yuchun Cao, Zhichao Gu

Study supervision: Bo Huang, Yuchun Cao

ACKNOWLEDGMENTS

We thank the specimen donors and research groups that contributed to this paper. Gene microarray detections were performed by Genminix Informatics Co. (Shanghai, China) and we thank Zhenhua Yang and Anbang Wu from this Company for bioinformatic analysis.

CONFLICTS OF INTEREST

The authors declare no financial conflicts of interest.

FUNDING

This work was supported by the National Natural Science Foundation of China (Grant No. 81472000).

REFERENCES

1. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 2008; 7:11–20.

2. Ward PS, Thompson CB. Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell. 2012; 21:297–308.

3. Li Y, Luo S, Ma R, Liu J, Xu P, Zhang H, Tang K, Ma J, Zhang Y, Liang X, Sun Y, Ji T, Wang N, et al. Upregulation of cytosolic phosphoenolpyruvate carboxykinase is a critical metabolic event in melanoma cells that repopulate tumors. Cancer Res. 2015; 75:1191–1196.

4. Etchegaray JP, Mostoslavsky R. Interplay between Metabolism and Epigenetics: A Nuclear Adaptation to Environmental Changes. Mol Cell. 2016; 62:695–711.

5. Alfarouk KO, Verduzco D, Rauch C, Muddathir AK, Adil HH, Elhassan GO, Ibrahim ME, David Polo Orozco J, Cardone RA, Reshkin SJ, Harguindey S. Glycolysis, tumor metabolism, cancer growth and dissemination. A new pH-based etiopathogenic perspective and therapeutic approach to an old cancer question. Oncoscience. 2014; 1:777–802. https://doi.org/10.18632/oncoscience.109.

6. Alfarouk KO, Muddathir AK, Shayoub ME. Tumor acidity as evolutionary spite. Cancers (Basel). 2011; 3:408–414.

7. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer. 2004; 4:891–899.

8. Kim JW, Dang CV. Cancer’s molecular sweet tooth and the Warburg effect. Cancer Res. 2006; 66:8927–8930.

9. Lopez-Lazaro M. The warburg effect: why and how do cancer cells activate glycolysis in the presence of oxygen? Anticancer Agents Med Chem. 2008; 8:305–312.

10. Zong WX, Rabinowitz JD, White E. Mitochondria and Cancer. Mol Cell. 2016; 61:667–676.

11. Ahn CS, Metallo CM. Mitochondria as biosynthetic factories for cancer proliferation. Cancer Metab. 2015; 3:1.

12. Weinberg SE, Chandel NS. Targeting mitochondria metabolism for cancer therapy. Nat Chem Biol. 2015; 11:9–15.

13. Owen OE, Kalhan SC, Hanson RW. The key role of anaplerosis and cataplerosis for citric acid cycle function. J Biol Chem. 2002; 277:30409–30412.

14. Peters-Wendisch PG, Kreutzer C, Kalinowski J, Patek M, Sahm H, Eikmanns BJ. Pyruvate carboxylase from Corynebacterium glutamicum: characterization, expression and inactivation of the pyc gene. Microbiology. 1998; 144: 915–927.

15. March JC, Eiteman MA, Altman E. Expression of an anaplerotic enzyme, pyruvate carboxylase, improves recombinant protein production in Escherichia coli. Appl Environ Microbiol. 2002; 68:5620–5624.

16. Dunn MF. Anaplerotic function of phosphoenolpyruvate carboxylase in Bradyrhizobium japonicum USDA110. Curr Microbiol. 2011; 62:1782–1788.

17. Reszko AE, Kasumov T, Pierce BA, David F, Hoppel CL, Stanley WC, Des Rosiers C, Brunengraber H. Assessing the reversibility of the anaplerotic reactions of the propionyl-CoA pathway in heart and liver. J Biol Chem. 2003; 278:34959–34965.

18. Phaneuf D, Labelle Y, Berube D, Arden K, Cavenee W, Gagne R, Tanguay RM. Cloning and expression of the cDNA encoding human fumarylacetoacetate hydrolase, the enzyme deficient in hereditary tyrosinemia: assignment of the gene to chromosome 15. Am J Hum Genet. 1991; 48:525–535.

19. Agsteribbe E, van Faassen H, Hartog MV, Reversma T, Taanman JW, Pannekoek H, Evers RF, Welling GM, Berger R. Nucleotide sequence of cDNA encoding human fumarylacetoacetase. Nucleic Acids Res. 1990; 18:1887.

20. Phaneuf D, Lambert M, Laframboise R, Mitchell G, Lettre F, Tanguay RM. Type 1 hereditary tyrosinemia. Evidence for molecular heterogeneity and identification of a causal mutation in a French Canadian patient. J Clin Invest. 1992; 90:1185–1192.

21. Mohamed S, Kambal MA, Al Jurayyan NA, Al-Nemri A, Babiker A, Hasanato R, Al-Jarallah AS. Tyrosinemia type 1: a rare and forgotten cause of reversible hypertrophic cardiomyopathy in infancy. BMC Res Notes. 2013; 6:362.

22. Palmieri F. The mitochondrial transporter family SLC25: identification, properties and physiopathology. Mol Aspects Med. 2013; 34:465–484.

23. Dutta B, Wallqvist A, Reifman J. PathNet: a tool for pathway analysis using topological information. Source Code Biol Med. 2012; 7:10.

24. Akiba T, Hiraga K, Tuboi S. Intracellular distribution of fumarase in various animals. J Biochem. 1984; 96:189–195.

25. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, Cerami E, Sander C, Schultz N. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013; 6:l1.

26. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, Antipin Y, Reva B, Goldberg AP, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012; 2:401–404.

27. Burns CG, Ohi R, Krainer AR, Gould KL. Evidence that Myb-related CDC5 proteins are required for pre-mRNA splicing. Proc Natl Acad Sci U S A. 1999; 96:13789–13794.

28. Ohi R, Feoktistova A, McCann S, Valentine V, Look AT, Lipsick JS, Gould KL. Myb-related Schizosaccharomyces pombe cdc5p is structurally and functionally conserved in eukaryotes. Mol Cell Biol. 1998; 18:4097–4108.

29. Ohi R, McCollum D, Hirani B, Den Haese GJ, Zhang X, Burke JD, Turner K, Gould KL. The Schizosaccharomyces pombe cdc5+ gene encodes an essential protein with homology to c-Myb. Embo J. 1994; 13:471–483.

30. Bernstein HS, Coughlin SR. Pombe Cdc5-related protein. A putative human transcription factor implicated in mitogen-activated signaling. J Biol Chem. 1997; 272:5833–5837.

31. Latchman DS. Transcription factors: an overview. Int J Biochem Cell Biol. 1997; 29:1305–1312.

32. Blackwood EM, Kadonaga JT. Going the distance: a current view of enhancer action. Science. 1998; 281:60–63.

33. Pennacchio LA, Bickmore W, Dean A, Nobrega MA, Bejerano G. Enhancers: five essential questions. Nat Rev Genet. 2013; 14:288–295.

34. Barrett LW, Fletcher S, Wilton SD. Regulation of eukaryotic gene expression by the untranslated gene regions and other non-coding elements. Cell Mol Life Sci. 2012; 69:3613–3634.

35. Isaacs JS, Jung YJ, Mole DR, Lee S, Torres-Cabala C, Chung YL, Merino M, Trepel J, Zbar B, Toro J, Ratcliffe PJ, Linehan WM, Neckers L. HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. Cancer Cell. 2005; 8:143–153.

36. Lee S, Nakamura E, Yang H, Wei W, Linggi MS, Sajan MP, Farese RV, Freeman RS, Carter BD, Kaelin WJ, Schlisio S. Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer. Cancer Cell. 2005; 8:155–167.

37. Adam J, Hatipoglu E, O’Flaherty L, Ternette N, Sahgal N, Lockstone H, Baban D, Nye E, Stamp GW, Wolhuter K, Stevens M, Fischer R, Carmeliet P, et al. Renal cyst formation in Fh1-deficient mice is independent of the Hif/Phd pathway: roles for fumarate in KEAP1 succination and Nrf2 signaling. Cancer Cell. 2011; 20:524–537.

38. Ooi A, Wong JC, Petillo D, Roossien D, Perrier-Trudova V, Whitten D, Min BW, Tan MH, Zhang Z, Yang XJ, Zhou M, Gardie B, Molinie V, et al. An antioxidant response phenotype shared between hereditary and sporadic type 2 papillary renal cell carcinoma. Cancer Cell. 2011; 20:511–523.

39. Harris AL. Hypoxia--a key regulatory factor in tumour growth. Nat Rev Cancer. 2002; 2:38–47.

40. Denko NC, Fontana LA, Hudson KM, Sutphin PD, Raychaudhuri S, Altman R, Giaccia AJ. Investigating hypoxic tumor physiology through gene expression patterns. Oncogene. 2003; 22:5907–5914.

41. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, Buechler P, Isaacs WB, Semenza GL, Simons JW. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res. 1999; 59:5830–5835.

42. Zhang H, Tang K, Zhang Y, Ma R, Ma J, Li Y, Luo S, Liang X, Ji T, Gu Z, Lu J, He W, Cao X, et al. Cell-free tumor microparticle vaccines stimulate dendritic cells via cGAS/STING signaling. Cancer Immunol Res. 2015; 3:196–205.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 23107